Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1PFE trade ideas

PFE : A high-risk high-reward opportunityThe exponential growth of Pfizer during the COVID era can be attributed significantly to its role as a vaccine producer. However, the current levels of PFE are even lower than the pre-COVID trading price. The current stock price is approaching the lowest levels witnessed during the COVID-induced market crash. Consequently, almost all the increase in price driven by the COVID vaccine narrative is not reflected in the current stock price. I perceive potential in Pfizer as a robust company at its current valuation. I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so. At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
NYSE:PFELong
by Sniper-Traders
Pfizer.... Start buildingPfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when. I have started a minor position in Pfizer today and plan to DCA weekly small amount until we form a bullish trend. Good luck!
NYSE:PFELong
by farmtrader15
1
Pfizer (NYSE: $PFE) Stock SinksKey Takeaway 1. Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling as much as 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013. That’s the largest single-day drop for Pfizer since January 2009. 2. Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5 billion, representing roughly zero growth from 2023’s forecasts and coming in well below analysts’ average 2024 projected sales of $62.6 billion, according to FactSet. 3. Notably, Pfizer said it expects 2024 sales for its Covid products—Paxlovid pills and the Comirnaty vaccine—to be about $8 billion, a nearly 90% drop from the roughly $57 billion of revenue its Covid series brought in last year.
NYSE:PFEShort
by DEXWireNews
Pfizer P/E tied to decline; strong dividend option?Pfizer has an extensive history of high dividend yield: 5.73% TTM, up significantly since the sharp 2020-2021 decline--payout ratio 90.08%. However, a significant decline in earnings is tied directly to a share price decline. Unsure if recovery is expected, good horizons: approval in EU (small) } Bad horizons: Pfizer's uncontested market share/exclusivity decline, lack of meaningful pipeline, . Can we expect a dividend increase?
NYSE:PFELong
by Vellefaux
1
Pfizer Drops After Pulling Obesity-Drug Study Following PatientPfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space. Pfizer (NYSE: PFE) - shares slumped Friday after the drugmaker said it would not advance a study of its two-dose obesity treatment, following a high level of side effects in patients involved in the Phase II trial. Pfizer said it would instead focus on a single-dose option. Trials of its danuglipron treated showed good results in weight loss but induced vomiting and nausea in patients, which led to what it called "high discontinuation rates" compared with those taking a placebo. Pfizer's Mikael Dolsten, president of worldwide research and development, in late October called the danuglipron study "our main opportunity here for getting data to review for obesity, in fact, to diabetes" in a call with investors. For Pfizer, a Setback in Weight-loss Market The decision marks a significant setback in Pfizer's ambitions to enter the weight-loss drug market, which is currently dominated by Novo Nordisk's Wegovy. Pfizer rival Eli Lilly (LLY) - Get Free Report last month also won approval for its own weight-loss treatment, Zepbound, from the Food and Drug Administration. At last check Pfizer stock was trading off 4.7% just above $28.91 That's a bit more than half its 52-week high near $55, set in mid-December 2022. Pfizer in October slashed its full-year sales and profit forecasts amid a slump in demand for covid treatments, It told investors it would write off around $4.6 billion in inventories of Paxlovid, its oral covid treatment, while taking a further $5.5 billion noncash charge against its third-quarter earnings. Price Momentum PFE is trading near the bottom of its 52-week range and below its 200-day simple moving average. What does this mean? Investors have been pushing the share price lower, and the stock still appears to have downward momentum. This is a negative sign for the stock's future value.
NYSE:PFEShort
by DEXWireNews
Pfizer: Big Pharma struggles in the post-COVID timesPfizer Inc. shares have reached their lowest levels since March 2020, during the height of the coronavirus pandemic. Since the beginning of 2023, the issuer's securities have declined due to reduced revenue from drug and COVID-19 vaccine sales. However, Pfizer's potential is not exhausted, as the company intends to introduce a new drug called Danuglipron to combat excess weight in the coming weeks. So today, let's look at the Pfizer Inc (NYSE: PFE) stock chart. On the D1 timeframe, support formed at 28.93, and resistance moved to 31.39. Quotes consolidated above the crucial level of 30.14. On the H1 timeframe, if there is a rebound from the 30.14 level, the target for a price increase can be placed at 33.98. In the medium term, the price could potentially reach 40.15. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:PFE
by RoboMarkets